References of "Revue de Pneumologie Clinique"
     in
Bookmark and Share    
Peer Reviewed
See detailIntérêt de la tomographie à émission de positons dans la prise en charge du cancer broncho-pulmonaire
Bury, Thierry ULg; Rigo, Pierre ULg

in Revue de Pneumologie Clinique (2000), 56(2), 125-31

18 FDG- PET is an imagining technique based on metabolic criteria rather than morphological criteria. (18) FDG- PET can demonstrate accelerated glycosis in cancer tissue related to increased transporter ... [more ▼]

18 FDG- PET is an imagining technique based on metabolic criteria rather than morphological criteria. (18) FDG- PET can demonstrate accelerated glycosis in cancer tissue related to increased transporter and glycolytic enzyme activity. Whole body PET is currently under validation in a growing number of indications during diagnostic and therapeutic assessment phases of cancer treatment. In the field of pulmonary oncology, (18) FDG- PET has already demonstrated its performance capacity to: 1) discriminate the malignant nature of a solitary pulmonary nodule, 2) improve sensitivity over CT for mediastinal assessment in small-cell lung cancer, 3) acquire whole body imaging to search for distant metastasis in patients with small-cell lung cancer; PET is particularly useful for evaluation of an adrenal mass, 4) complement CT imaging to better dissociate tumor residue or recurrence from post-therapeutic sequelae in small-cell lung cancer. Information provided by (18) FDG- PET is thus clinically relevant as it allows better dissociation of a benign process from a malignant process and better precision of small-cell lung cancer extension without necessitating systematic invasive exploration. [less ▲]

Full Text
Peer Reviewed
See detailLe role du PAF et de ses antagonistes dans l'asthme bronchique.
MASSION, Paul ULg; Frans, A.

in Revue de Pneumologie Clinique (1992), 48(2), 49-57

Inhalation of the platelet activating factor (PAF) produces symptoms of bronchial asthma, a disease in which PAF plays an important role. This lipid mediator released by many kinds of cells exerts its ... [more ▼]

Inhalation of the platelet activating factor (PAF) produces symptoms of bronchial asthma, a disease in which PAF plays an important role. This lipid mediator released by many kinds of cells exerts its effects on blood cells and on cells of the bronchial wall both directly and indirectly. The crucial role played by PAF in the inflammatory cascades explains the current interest in specific PAF antagonists. These antagonists have both bronchodilator and anti-inflammatory properties and act simultaneously as beta-adrenoceptor agonists and corticosteroids. The first clinical trials of PAF antagonists in the treatment of resistant asthma have given results that are interesting but not superior to those obtained with the conventional anti-asthmatic drugs. The indications for PAF antagonists combined with other specific antagonists will soon be determined. [less ▲]

Detailed reference viewed: 25 (2 ULg)